Overview
On 9 June 2010, orphan designation (EU/3/10/749) was granted by the European Commission to NovImmune B.V., the Netherlands, for recombinant human anti-interferon gamma monoclonal antibody for the treatment of haemophagocytic lymphohistiocytosis.
This medicine is now known as emapalumab.
The sponsorship was transferred to Swedish Orphan Biovitrum AB (publ), Sweden, in June 2019.
Key facts
Active substance |
Recombinant human anti-interferon gamma monoclonal antibody (emapalumab)
|
Intended use |
Treatment of haemophagocytic lymphohistiocytosis
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/10/749
|
Date of designation |
09/06/2010
|
Sponsor |
Swedish Orphan Biovitrum AB (publ) |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: